Arcus biosciences stock.
Jarrett Jennifer, the Chief Operating Officer of Arcus Biosciences Inc, sale 45,000 shares at $20.25 during a trade that took place back on Jul 28, which means that Jarrett Jennifer is holding 336,566 shares at $911,250 based on the most recent closing price. Stock Fundamentals for RCUS. Current profitability levels for the company are sitting at:
Get the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. See the current price, performance outlook, earnings date, dividend yield, fair value and more. You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Arcus Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, ... Unique to Barchart.com, Opinions analyzes a stock or commodity using …Jun 15, 2023 · I last covered Arcus Biosciences (NYSE:RCUS) for Seeking Alpha back in March 2020, giving the company' stock a "BUY" rating - more than 3 years later, Arcus stock has reached a value of $20 at the ...
Competitors. RCUS | Complete Arcus Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Arcus Biosciences Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 10 stock analysts, the average 12-month stock price forecast for RCUS stock stock is $42.6, which predicts an increase of 165.09%. The lowest target is $23 and the highest is $70. On average, analysts rate RCUS stock stock as a strong buy.
Arcus Biosciences last posted its quarterly earnings results on November 7th, 2023. The reported ($0.94) EPS for the quarter, beating the consensus estimate of ($1.12) by $0.18. The firm earned $32 million during the quarter, compared to analysts' expectations of $27.57 million. Its revenue for the quarter was down 3.0% on a year-over …
Camaraderie, teamwork, integrity. The complexity and cross-functional nature of what we do makes strong teamwork essential to our success. We take pride in hard work and approach our mission with a great sense of urgency. We embrace innovative mindsets and the change this brings. And finally, we aspire to operate with simplicity and common ... Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and ...HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the third quarter ended September 30, 2022 and provided a pipeline …– 35-45% Reduction in Risk of Progression or Death and a Doubling of mPFS Were Observed in the Domvanalimab-Containing Study Arms, Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC – – With Median Follow-Up of Approximately 12 Months, Both Domvanalimab-Containing Study Arms Also Improved …
Nov 27, 2023 · Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price ...
Dec 1, 2023 · Arcus Biosciences Stock Forecast. ... According to 10 stock analysts, the average 12-month stock price forecast for RCUS stock stock is $42.6, which predicts an ...
Arcus Biosciences Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time RCUS stock price.FOSTER CITY, Calif., & HAYWARD, Calif., May 15, 2023--Gilead Sciences, Inc. (Nasdaq:GILD) and Arcus Biosciences, Inc. (NYSE:RCUS) today announced that the companies have expanded the previously ...Stay up to date on Arcus Biosciences analyst ratings. If you are interested in following small-cap stock news and performance you can start by tracking it here.Dr. Jaen owns 218,258 shares of Arcus Biosciences stock worth more than $3,127,637 as of October 29th. This net worth approximation does not reflect any other assets that Dr. Jaen may own. Additionally, Dr. Jaen receives a salary of $931,140.00 as President at Arcus Biosciences. Learn More about Juan C. Jaen's net worth.During the last session, Arcus Biosciences Inc (NYSE:RCUS)’s traded shares were 0.79 million, with the beta value of the company hitting 0.69. At the end of the trading day, the stock’s price was $16.07, reflecting an intraday gain of 6.71% or $1.01. The 52-week high for the RCUS share is $36.13 ...
Best Mid-Cap Companies (2021) Dropped off in 2022. #27. Best Small Cap Companies (2021) Dropped off in 2022. Arcus Biosciences (RCUS) Stock Price Performance. Arcus Biosciences (RCUS) Stock Key ... Arcus Biosciences Inc. historical stock charts and prices, analyst ratings, financials, and today’s real-time RCUS stock price.AstraZeneca and Arcus have a clinical collaboration on Pacific-8 a Phase III study evaluating our anti-TIGIT antibody domvanalimab plus durvalumab (Imfinzi®) for stage 3 non-small cell lung cancer with curative intent. Welcome to investor relations at Arcus Biosciences. We're at the forefront of designing highly-combinable, best-in-class ... Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a pipeline update on its clinical-stage investigational molecules – targeting TIGIT ...Description. Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates.
Discover historical prices for RCUS stock on Yahoo Finance. View daily, weekly or monthly format back to when Arcus Biosciences, Inc. stock was issued. ... Arcus Biosciences, Inc. (RCUS) NYSE ...
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is …Arcus Biosciences, Inc. Stock price Equities RCUS US03969F1093 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar Company Financials Consensus Revisions Funds and ETFs Financials (USD) More Fundamentals * Assessed data Chart Arcus Biosciences, Inc. Duration Period Style Dynamic ChartApr 12, 2023 · Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 6.96% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $18.51 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to date ... Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently up 4.71% so far this month. During the month of November, Arcus Biosciences Inc’s stock price has reached a high of $16.76 and a low of $15.35. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $14.33. Year to …Zimberelimab was in-licensed by Arcus to enable the development of precision combination regimens with full line-of-sight to the commercialization of innovative therapies for all patients who may benefit. Arcus is evaluating zimberelimab in combination with multiple molecules within the Arcus portfolio, including several registrational Phase 3 ...Nov 7, 2023 · Arcus Biosciences, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was USD 32 million compared to USD 33 million a year ago. View the latest Arcus Biosciences Inc. (RCUS) stock price, news, historical charts, analyst ratings and financial information from WSJ.A high-level overview of Arcus Biosciences, Inc. (RCUS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and …I last covered Arcus Biosciences (NYSE:RCUS) for Seeking Alpha back in March 2020, giving the company' stock a "BUY" rating - more than 3 years later, Arcus stock has reached a value of $20 at the ...
Vir Biotechnology Inc. 9.51. +0.02. +0.21%. Get Arcus Biosciences Inc (RCUS:NYSE) real-time stock quotes, news, price and financial information from CNBC.
In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies.The parties will co-develop Gilead-optioned programs globally and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.
Nov 8, 2023 · On November 8, 2023, Arcus Biosciences Inc (RCUS) experienced a significant increase in its stock performance. According to data from CNN Money, the 12 analysts offering 12-month price forecasts for RCUS had a median target of $38.00, with a high estimate of $70.00 and a low estimate of $23.00. HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today provided updates on clinical programs and key milestones anticipated in 2022.Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an exercise price ...An in-depth examination of risks revealed 2 warning signs for Arcus Biosciences that readers should think about before committing capital to this stock. Of course, you might find a fantastic ...During the last session, Arcus Biosciences Inc (NYSE:RCUS)’s traded shares were 0.88 million, with the beta value of the company hitting 0.75. At the end of the trading day, the stock’s price was $16.01, reflecting an intraday loss of -2.67% or -$0.44. The 52-week high for the RCUS share is $36.15 мая 2023 г. ... Gilead is paying $35 million cash to expand an existing oncology partnership with Arcus Biosciences into inflammatory diseases.Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced seven accepted abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be …You can hold this stock in a SIPP, ISA, JISA and Trading Account. Market Cap. $1.579bn. Div. Yield. -. Volume. 294,372. Open Price. $22.22. Prev. Close. $21.99.HAYWARD, Calif.--(BUSINESS WIRE)--Nov. 27, 2023-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company …HAYWARD, Calif., December 09, 2022--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the ...Dec 1, 2023 · marketbeat.com - September 22 at 4:25 AM. Truist Financial Remains a Buy on Arcus Biosciences (RCUS) markets.businessinsider.com - September 19 at 6:53 AM. Granahan Investment Management LLC Has $10.52 Million Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS) marketbeat.com - September 11 at 5:40 AM. Nov 20, 2023 · Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s pipeline products include Domvanalimab, an anti-TIGIT investigational monoclonal antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to ...
Arcus Biosciences Inc Stock Price History. Arcus Biosciences Inc’s price is currently down 6.96% so far this month. During the month of April, Arcus Biosciences Inc’s stock price has reached a high of $18.51 and a low of $16.94. Over the last year, Arcus Biosciences Inc has hit prices as high as $36.13 and as low as $15.70. Year to …Complete Arcus Biosciences Inc. stock information by Barron's. View real-time RCUS stock price and news, along with industry-best analysis.Shares of Arcus Biosciences ( RCUS 3.94%) jumped by as much as 21% in premarket trading Thursday morning. The biotech's stock is heating up in early morning action today on the news that Gilead ...Instagram:https://instagram. best forex broker for metatrader 5forex signal providersihgnbest high dividend growth stocks Track Arcus Biosciences Inc (RCUS) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors arm stock forecastduckid Find the latest Arcus Biosciences, Inc. (RCUS) stock quote, history, news and other vital information to help you with your stock trading and investing. samsara valuation Mizuho Securities analyst Mara Goldstein maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price targe...Arcus Biosciences (RCUS) stock price prediction is 40.382134862897 USD. The Arcus Biosciences stock forecast is 40.382134862897 USD for 2024 November 27, ...